drugset / Trial / NCT05661357
Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression
Phase 4
Unknown
51 enrolled
Zhongnan Hospital
Huangshi Central Hospital · collabHubei Cancer Hospital · collabSir Run Run Shaw Hospital · collabThe First People's Hospital of Tianmen · collab
NaSingle-groupOpen-labelTreatment
Summary
Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures
Timeline
- Start
- 2023-01-01
- Primary completion
- 2025-01-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Fruquintinib | Small molecule | 3 mg | — |